{"doi":"10.1016/j.jtho.2021.08.061","title":"OA09.01 First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA","abstract":null,"journal":"Journal of Thoracic Oncology","year":2021,"id":613398,"datarank":0.47670807455219194,"base_score":3.1780538303479458,"endowment":3.1780538303479458,"self_citation_contribution":0.47670807455219194,"citation_network_contribution":0.0,"self_endowment_contribution":0.47670807455219194,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":23,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1580258,"name":"T. Ciuleanu","orcid":null,"position":1,"is_corresponding":false},{"id":1580259,"name":"M. Cobo","orcid":null,"position":2,"is_corresponding":false},{"id":1580260,"name":"M. Schenker","orcid":null,"position":3,"is_corresponding":false},{"id":1580261,"name":"B. Zurawski","orcid":null,"position":4,"is_corresponding":false},{"id":826844,"name":"J. Menezes","orcid":null,"position":5,"is_corresponding":false},{"id":1558134,"name":"E. Richardet","orcid":null,"position":6,"is_corresponding":false},{"id":1316173,"name":"J. Bennouna","orcid":null,"position":7,"is_corresponding":false},{"id":1316178,"name":"E. Felip","orcid":null,"position":8,"is_corresponding":false},{"id":1580262,"name":"O. Juan-Vidal","orcid":null,"position":9,"is_corresponding":false},{"id":1580263,"name":"A. Alexandru","orcid":null,"position":10,"is_corresponding":false},{"id":1580264,"name":"H. Sakai","orcid":null,"position":11,"is_corresponding":false},{"id":1580265,"name":"E. De La Mora Jimenez","orcid":null,"position":12,"is_corresponding":false},{"id":1565,"name":"L. Paz-Ares","orcid":null,"position":13,"is_corresponding":false},{"id":132457,"name":"M. Reck","orcid":null,"position":14,"is_corresponding":false},{"id":1580266,"name":"T. John","orcid":null,"position":15,"is_corresponding":false},{"id":1580267,"name":"N. Hu","orcid":null,"position":16,"is_corresponding":false},{"id":10784,"name":"X. Zhang","orcid":"0000-0001-9155-5308","position":17,"is_corresponding":false},{"id":1580268,"name":"P. Tran","orcid":null,"position":18,"is_corresponding":false},{"id":1580269,"name":"D.J. Grootendorst","orcid":null,"position":19,"is_corresponding":false},{"id":26375,"name":"S. Lu","orcid":"0000-0002-8814-1670","position":20,"is_corresponding":false},{"id":725613,"name":"D. Carbone","orcid":"0000-0003-0208-2188","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"OA09.01 First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA","abstract":null,"is_dataset_classified":null,"base_score":3.1780538303479458,"endowment":3.1780538303479458,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"23304386","pmcid":null,"openalex_id":"https://openalex.org/W3207731879","authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[{"year":2022,"count":6},{"year":2023,"count":10},{"year":2024,"count":5},{"year":2025,"count":2}],"oa_status":"closed","license":"http://www.elsevier.com/open-access/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S1556086421024849?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1556086421024849?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.jtho.2021.08.061","host_type":"journal"},{"url":"https://inserm.hal.science/inserm-03540850","host_type":"repository"}],"fields_of_study":["Brain Metastases and Treatment","Lung Cancer Treatments and Mutations","Lung Cancer Research Studies"],"mesh_terms":[],"keywords":["Medicine","Nivolumab","Ipilimumab","Oncology","Internal medicine","Clinical endpoint","Lung cancer","Overall survival","Brain metastasis","Clinical trial","Cancer","Immunotherapy","Metastasis"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-02T07:57:55.857924Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}